Clinical Trials List
2020-10-15 - 2025-12-31
Phase I/II
Recruiting4
Terminated4
ICD-10C50.911
Malignant neoplasm of unspecified site of right female breast
ICD-10C50.912
Malignant neoplasm of unspecified site of left female breast
ICD-10C50.919
Malignant neoplasm of unspecified site of unspecified female breast
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9174.9
Malignant neoplasm of female breast, unspecified
-
Trial Applicant
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/04/01
Investigators and Locations
Co-Principal Investigator
- Ta-Chung Chao Division of Radiation Therapy
- Jiun-I Lai Division of Radiation Therapy
- 邱仁輝 Division of General Surgery
- Chun-Yu Liu Division of Hematology & Oncology
- Chi-Cheng Huang Division of General Surgery
- Yi-Fang Tsai Division of General Surgery
- 賴亦貞 Division of Radiology
- 林燕淑 Division of General Surgery
- 馮晉榮 未分科
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Chun-Hui Lee Division of General Internal Medicine
- Kuo-Ting Lee Division of Hematology & Oncology
- Yao-Lung Kuo 未分科
- 楊舜如 Division of Hematology & Oncology
- Jui-Hung Tsai Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Wen-Chi Shen Division of Hematology & Oncology
- Chan-Keng Yang Division of Hematology & Oncology
- Chun-Hsiu Liu Division of Ophthalmology
- 沈士哲 Division of General Surgery
- Wen-Ling Kuo Division of General Surgery
- Chi-Chang Yu Division of General Surgery
- 周旭桓 Division of General Surgery
- 張潤忠 Division of Radiology
- Yung-Chang Lin Division of Hematology & Oncology
- Mengting Peng Division of Hematology & Oncology
- TSU-YI CHAO Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 林柏翰 Division of General Surgery
- 張端瑩 Division of Hematology & Oncology
- 蔡立威 Division of General Surgery
- Wei-Wu Chen Division of Hematology & Oncology
- MING-YANG WANG Division of General Surgery
- YEN-SHEN LU Division of Hematology & Oncology
- 陳怡君 Division of Hematology & Oncology
- 羅喬 Division of General Surgery
- 林季宏 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- TSU-YI CHAO Division of Hematology & Oncology
- KA-WAI TAM Division of General Surgery
- HUI-WEN LIU Division of Hematology & Oncology
- 蘇智銘 Division of General Surgery
- Wei-Hong Cheng Division of Hematology & Oncology
- CHIN-SHENG HUNG Division of General Surgery
The Actual Total Number of Participants Enrolled
0 Terminated
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- 何景良 Division of Hematology & Oncology
- 陳佳宏 Division of Hematology & Oncology
- 賴學緯 Division of Hematology & Oncology
- 吳宜穎 Division of Hematology & Oncology
- 黃子權 Division of Hematology & Oncology
- 張平穎 Division of Hematology & Oncology
- 葉人華 Division of Hematology & Oncology
- 陳宇欽 Division of Hematology & Oncology
- 廖國秀 Division of General Surgery
The Actual Total Number of Participants Enrolled
0 Terminated
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
34 participants
-
Global
350 participants
